Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
06/2003
06/12/2003WO2003047554A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts
06/12/2003WO2003047552A2 Pharmaceutical composition comprising a 5ht1 receptor agonist
06/12/2003WO2003047519A2 'compressed annular tablet with molded triturate tablet for oral and intraoral'
06/12/2003WO2003047516A2 Pyrimidine compounds
06/12/2003WO2003047500A2 Vaccine and method for treatment of motor neurone diseases
06/12/2003WO2003047499A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting
06/12/2003WO2003047367A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof
06/12/2003WO2003005962A3 Methods for treatment of cognitive and menopausal disorders with d-threo methylphenidate
06/12/2003WO2002103031A3 Methods for detecting and treating the early onset of aging-related conditions
06/12/2003WO2002064094A3 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders
06/12/2003WO2001088126A8 REGULATION OF HUMAN α1Α ADRENERGIC RECEPTOR-LIKE G PROTEIN-COUPLED RECEPTOR
06/12/2003WO2001071007A3 GENETIC POLYMORPHISM OF MxA PROTEIN AND USE THEREOF
06/12/2003US20030109683 Hybrid proteins; controlling gene expression in gene therapy; Parkinson's disease
06/12/2003US20030109671 Therapeutic agents and methods of use thereof for the modulation of angiogenesis
06/12/2003US20030109585 Novel crystalline polymorph of venlafaxine hydrochloride and methods for the preparation thereof
06/12/2003US20030109576 Tartrate salts of (r) -3-n,n- dicyclobutylamino-8-fluoro-3,4-dihydro-2h-1- benzopyran-5-carboxamide
06/12/2003US20030109570 Activate a peroxisome proliferator-activated receptor (PPAR) alpha or gamma which is an intranuclear transcription factor. The compound may be used as an active ingredient to give a drug for preventing or treating a variety of diseases
06/12/2003US20030109566 Therapeutic treatment of diseases in optic nerve and the like.
06/12/2003US20030109564 Treating: allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
06/12/2003US20030109562 Antidepressant azaheterocyclylmethyl derivatives of 7,8-dihydro-1, 6,9-trioxa-3-aza-cyclopenta[a]naphthalene
06/12/2003US20030109546 Treatment of psychotic disorders comprising co-therapy with anticonvulsant derivatives and atypical antipsychotics
06/12/2003US20030109545 Their solvates and/or hydrates exhibiting an affinity and a selectivity for arginine-vasopressin V1b receptors or for both V1b and V1a receptors.
06/12/2003US20030109544 Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
06/12/2003US20030109539 Treating a condition selected from the group consisting of anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and improved cognition, in a subject in need thereof comprising administering a compound
06/12/2003US20030109538 Pyrmidine derivatives as selective inhibitors of cox-2
06/12/2003US20030109536 Treatment of a variety of central nervous system (CNS) disorders in humans, domesticated companion animals and livestock animals. treatment of anxiety, depression, a sleep disorder, attention deficit disorder, or Alzheimer's dementia,
06/12/2003US20030109535 GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure:prodrugs, stereoisomers and drugs
06/12/2003US20030109533 New benzenesulphonamide compounds
06/12/2003US20030109532 Modulators of dopamine neurotransmission
06/12/2003US20030109530 Diabetes, insulin resistance, dyslipidemia, obesity, high blood pressure, atherosclerosis, retinopathies and neurodegenerative disorders; synthesis by reacting a biguanide with an aldehyde, semiacetal or acetal in presence of acid catalyst
06/12/2003US20030109527 Novel hydroxy diphenylurea sulfonamides, compositions and intermediates thereof. The hydroxy
06/12/2003US20030109526 Azo amino acids derivatives
06/12/2003US20030109521 Aryl substituted thiazolidinones and the use thereof
06/12/2003US20030109518 Substituted 1,4-benzodiazepines and uses thereof
06/12/2003US20030109516 Tetrahydroquinazoline-2,4-diones and therapeutic uses thereof
06/12/2003US20030109504 Inhibit metabotropic glutamate receptor activity, or activation, for use in the treatment of movement disorders associated with a poverty of movement (e.g. Parkinson's disease). The compounds are particularly useful when used in
06/12/2003US20030109497 Novel imidazolidine derivatives, their preparation and their use
06/12/2003US20030109491 Use of heparinoid derivatives for the treatment and diagnosis of disorders which can be treated with heparinoids
06/12/2003US20030109476 Compositions and methods for the prevention and treatment of Huntington's disease
06/12/2003US20030109454 Modulating agents and methods for enhancing or inhibiting cadherin-mediated functions are provided. The modulating agents comprise at least an HAV binding motif, an analogue or peptidomimetic thereof, or an antibody or fragment thereof
06/12/2003US20030109435 Methods of inhibiting amyloid toxicity
06/12/2003US20030109419 Detection and tested for an ability to treat a psychotic disorder in a patient in need of such treatment. The invention provides a method for screening candidate drugs for anti-psychotic drug activity, preferably atypical
06/12/2003US20030109417 Administering substance P receptor antagonist selected from the group consisting of L 742694, L 758298, and LY 303241, a non-toxic magnesium compound and a pharmaceutically acceptable vehicle
06/12/2003US20030109041 Culture regeneration of nervous systems; cell differentiation; wound healing agent
06/12/2003US20030109039 Enriched central nervous system stem cell and porgenitor cell populations, and methods for identifying, isolating and enriching for such populations
06/12/2003US20030109022 Asp2
06/12/2003US20030108928 MID 241 receptor, a novel G-protein coupled receptor
06/12/2003US20030108906 Signal transduction, gene expression of pain sequences; genetic engineering
06/12/2003US20030108617 Use of a formulation made of or containing at least one dissimilated milk serum
06/12/2003US20030108603 Mixture of protein, hydrophilic polymer, group 1a alkyl sulfate and sugar
06/12/2003US20030108593 Reduction inhibitory agent for active oxygen eliminating activity
06/12/2003US20030108544 Compositions and methods for the diagnosis and treatment of tumor
06/12/2003US20030108539 Cell-permeable peptide inhibitors of the JNK signal transduction pathway
06/12/2003US20030107149 Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
06/12/2003CA2471794A1 Use of 2-hydroxy or 2-acetyloxy-4-trifluoromethylbenzoic acid derivatives as an agent for the treatment and prevention of mild cognitive impairment
06/12/2003CA2469227A1 New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
06/12/2003CA2469130A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease
06/12/2003CA2469092A1 Copolymer 1 vaccine and methods for treatment of amyotrophic lateral sclerosis (als)
06/12/2003CA2469078A1 Immunotherapeutic methods and systems
06/12/2003CA2468967A1 N-aryl-n'-arylcycloalkyl-urea derivatives as mch antagonists for the treatment of obesity
06/12/2003CA2468927A1 Ring fused pyrazole derivatives
06/12/2003CA2468893A1 Imidazopyridines, pyrimidines and triazines for enhancing cognition as gaba-a alpha 5 receptor subtype ligands
06/12/2003CA2468558A1 "compressed annular tablet with molded triturate tablet for oral and intraoral"
06/12/2003CA2468525A1 Process for the preparation of compositions having an increased amount of pharmaceutically active salts of rotamers of 4-[4-[(1r)-[4-(trifluoromethyl)phenyl]-2-methoxyethyl]-(3s)-methyl-1-piperazinyl]-4-methyl-1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]
06/12/2003CA2468349A1 Pyrimidine compounds
06/12/2003CA2468067A1 Metabotropic glutamate receptor-5 modulators
06/12/2003CA2468044A1 Use of a compound in the treatment of sleep disorders and the like, in providing refreshedness on waking and a method for the treatment of grogginess therewith
06/12/2003CA2468040A1 Preparation of cis-fused 3,3a,8,12b-tetrahydro-2h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives
06/12/2003CA2467333A1 Methods for monitoring amyotrophic lateral sclerosis
06/12/2003CA2467073A1 Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases
06/12/2003CA2466697A1 Pharmaceutical compositions containing 3,4-propinoperhydropurines and uses thereof for blocking neuronal transmission
06/12/2003CA2466649A1 Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
06/11/2003EP1318150A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
06/11/2003EP1318149A1 Amidine derivatives, their preparation and application as medicines and pharmaceutical compositions containing them
06/11/2003EP1318147A1 Novel pyrimidine derivative and novel pyridine derivative
06/11/2003EP1317924A1 Kit for reducing aching caused by pde-v inhibitors
06/11/2003EP1317541A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
06/11/2003EP1317540A2 Imidazoline receptor homologs
06/11/2003EP1317537A2 G-csf analog compositions and methods
06/11/2003EP1317486A1 Interferon-alpha induced gene
06/11/2003EP1317485A2 Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
06/11/2003EP1317479A2 Methods and compositions for diseases associated with amyloidosis
06/11/2003EP1317477A2 Muteins of the cgrp 1-7 peptide fragment and use thereof as nicotinic neuronal receptor enhancers
06/11/2003EP1317465A1 Purine derivatives
06/11/2003EP1317454A2 Caspase inhibitors and uses thereof
06/11/2003EP1317453A1 Isoxazoles and their use as inhibitors of erk
06/11/2003EP1317452A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317450A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317449A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317448A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317447A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317444A1 Pyrazole compounds useful as protein kinase inhibitors
06/11/2003EP1317433A2 Inhibitors of glycogen synthase kinase 3
06/11/2003EP1317430A1 (2-azabicyclo 2.2.1]hept-7-yl)methanol derivatives as nicotinic acetylcholine receptor agonists
06/11/2003EP1317428A1 Pyrrolidine-2-carboxylic acid hydrazide derivatives for use as metalloprotease inhibitors
06/11/2003EP1317427A1 Method for producing chiral compounds
06/11/2003EP1317426A1 Beta-thio-amino acids
06/11/2003EP1317424A2 Polyamine analogues as therapeutic and diagnostic agents
06/11/2003EP1317421A1 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
06/11/2003EP1317420A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors
1 ... 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 ... 1833